Cholesterol lowering treatment for those with Chol > 8 mmol/L and total CVD risk < 30%
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$1923–39476
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
3
Tier A · 55 studies
Source agreement
material
sources differ
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources differ by 20.5x - a material difference.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 53 studies, varied methods — explore the spread, not a single number.
Health-system
$630
median · n=50
Societal
$2,303
median · n=3
Filter the cohort
$704median of 53 studies · IQR $215–$2,346 · 2 cost-saving
Published study estimates ($/DALY)Tier B · context only
DCP3 (2013 reference)$11600median · 2 studies
range $1200–$22000/DALY. Varied methods — not directly comparable.
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Cholesterol lowering treatment for those with Chol > 8 mmol/L and total CVD risk < 30%? Select a country above, then open its intelligence page.